Skip to contentT
TScan Therapeutics, Inc.
T
TCRXTScan Therapeutics, Inc. Q3 2023 · 10-Q
Revenue$3.89M$3.89M+15.6% vs Q3 2022 Net Income-$23.00M-$23.00MN/M vs Q3 2022 EPS Diluted-$0.24-$0.24N/M vs Q3 2022 Operating Income-$24,748,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$6,598,000N/M Margins · derivedOperating margin-636.7%−143.7 pt vs Q3 2022
Net margin-591.6%−108.6 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 9, 2023 · 40 d after period end